777 related articles for article (PubMed ID: 32927274)
1. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
2. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
5. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
6. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
7.
Biton J; Mansuet-Lupo A; Pécuchet N; Alifano M; Ouakrim H; Arrondeau J; Boudou-Rouquette P; Goldwasser F; Leroy K; Goc J; Wislez M; Germain C; Laurent-Puig P; Dieu-Nosjean MC; Cremer I; Herbst R; Blons H; Damotte D
Clin Cancer Res; 2018 Nov; 24(22):5710-5723. PubMed ID: 29764856
[No Abstract] [Full Text] [Related]
8. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
10. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
11. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.
Li H; Yang L; Wang Y; Wang L; Chen G; Zhang L; Wang D
BMC Bioinformatics; 2023 Apr; 24(1):155. PubMed ID: 37072703
[TBL] [Abstract][Full Text] [Related]
13. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
14. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
[TBL] [Abstract][Full Text] [Related]
15. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
16. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract][Full Text] [Related]
17. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
[TBL] [Abstract][Full Text] [Related]
18. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
20. Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.
Wang Q; Tang Z; Li C; Li X; Su C
Front Immunol; 2023; 14():1297588. PubMed ID: 37954616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]